No Data
No Data
AUBEX: Supplementary explanation of financial results for the fiscal year ending March 31, 2024
AUBEX: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
AuBEX Corp Sees FY Net Y460.00M
AuBEX Corp. also released the following forecasts: GROUP 1st Half To Year Ending Sep 2024 Mar 2025 Revenue Y2.80 bln Y5.70 bln Operating
Daiwa House, Meiji HD, Shiseido, Sumitomo Electric (10th) (1301-5998)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/10 (Fri) <1301>Kyokuyo <1379>Hokuto <1414>Show Bond <1420>Sanyo H<1429>Japan Aqua <1431>Ribwork<1435>Robot Home <1438>Gifu Landscaping<1
Aubex Therapeutics Launches to Revolutionize Cancer Treatment With Novel Compounds Directed Toward the Tumor Microenvironment
Aubex Therapeutics Inc., a pioneering biotechnology firm, today announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer,
AuBEX Corp Sees FY Net Y390.00M
AuBEX Corp. also released the following forecasts: GROUP Year Ending Mar 2024 Revenue Y5.40 bln Operating Profit Y550.00 mln Pretax Profit Y5
No Data